Ventrus gains on PhIII anal fissures data for diltiazem cream; awaits possible replication of EU study
This article was originally published in Scrip
Executive Summary
Ventrus Biosciences, a US firm focused on late-stage GI compounds, said that its diltiazem cream for anal fissures, VEN 307, met the primary endpoint, showing a statistically significant reduction in anal pain on defecation after four weeks compared to placebo in a pivotal Phase III trial conducted in Europe. The company’s share price shot up 19% in early trading and closed up $1.62 (15%), to $12.58 as the firm moves toward a US NDA filing.